Michael Conroy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michael Conroy has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Patrick M. Forde
Trinity St. James’s Cancer Institute, School of Medicine, Trinity College Dublin, Dublin, Ireland
25 shared publications - Jaime Wehr
The Sidney Kimmel Comprehensive Cancer Center 1 , Johns Hopkins University School of Medicine, Baltimore, Maryland
24 shared publications - Jarushka Naidoo
Beaumont Hospital, Dublin, Ireland
24 shared publications - Valsamo Anagnostou
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA
24 shared publications - Aliyah Pabani
The Sidney Kimmel Comprehensive Cancer Center 1 , Johns Hopkins University School of Medicine, Baltimore, Maryland
23 shared publications - Archana Balan
The Sidney Kimmel Comprehensive Cancer Center 1 , Johns Hopkins University School of Medicine, Baltimore, Maryland
23 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (7) , e2600067
Emergence of Microsatellite Instability in an Oncogene-Driven Non–Small Cell Lung Cancer Harboring a Canonical EGFR Mutation: A Molecular Tumor Board Discussion
- 1 July 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (7) , e2600067
Open AccessEmergence of Microsatellite Instability in an Oncogene-Driven Non–Small Cell Lung Cancer Harboring a Canonical EGFR Mutation: A Molecular Tumor Board Discussion
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S9 from Serial Plasma Comprehensive Genomic Profiling Captures Therapy Resistance and Guides Management of Non–Small Cell Lung Cancer
Supplementary Table S9. Putative uncommon on-target drivers of EGFR TKI resistance.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S9 from Serial Plasma Comprehensive Genomic Profiling Captures Therapy Resistance and Guides Management of Non–Small Cell Lung Cancer
Supplementary Table S9. Putative uncommon on-target drivers of EGFR TKI resistance.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Serial Plasma Comprehensive Genomic Profiling Captures Therapy Resistance and Guides Management of Non–Small Cell Lung Cancer
Supplementary Table S4. Description of pCGP-informed clinical management.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Serial Plasma Comprehensive Genomic Profiling Captures Therapy Resistance and Guides Management of Non–Small Cell Lung Cancer
Supplementary Table S4. Description of pCGP-informed clinical management.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Serial Plasma Comprehensive Genomic Profiling Captures Therapy Resistance and Guides Management of Non–Small Cell Lung Cancer
Figure S2. Actionable alterations identified on all instances of first pCGP.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Serial Plasma Comprehensive Genomic Profiling Captures Therapy Resistance and Guides Management of Non–Small Cell Lung Cancer
Figure S2. Actionable alterations identified on all instances of first pCGP.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Serial Plasma Comprehensive Genomic Profiling Captures Therapy Resistance and Guides Management of Non–Small Cell Lung Cancer
Supplementary Table S1. Context of first pCGP assays.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Serial Plasma Comprehensive Genomic Profiling Captures Therapy Resistance and Guides Management of Non–Small Cell Lung Cancer
Supplementary Table S1. Context of first pCGP assays.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S10 from Serial Plasma Comprehensive Genomic Profiling Captures Therapy Resistance and Guides Management of Non–Small Cell Lung Cancer
Supplementary Table S10. Drivers of EGFR TKI resistance.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S10 from Serial Plasma Comprehensive Genomic Profiling Captures Therapy Resistance and Guides Management of Non–Small Cell Lung Cancer
Supplementary Table S10. Drivers of EGFR TKI resistance.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Serial Plasma Comprehensive Genomic Profiling Captures Therapy Resistance and Guides Management of Non–Small Cell Lung Cancer
Figure S5. Mechanisms of resistance to EGFR TKI according to first line of therapy received.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Serial Plasma Comprehensive Genomic Profiling Captures Therapy Resistance and Guides Management of Non–Small Cell Lung Cancer
Figure S5. Mechanisms of resistance to EGFR TKI according to first line of therapy received.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Serial Plasma Comprehensive Genomic Profiling Captures Therapy Resistance and Guides Management of Non–Small Cell Lung Cancer
Figure S1. Landscape of all alterations identified by pCGP.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Serial Plasma Comprehensive Genomic Profiling Captures Therapy Resistance and Guides Management of Non–Small Cell Lung Cancer
Figure S1. Landscape of all alterations identified by pCGP.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 3 from Serial Plasma Comprehensive Genomic Profiling Captures Therapy Resistance and Guides Management of Non–Small Cell Lung Cancer
Comutations on pCGP in EGFRm NSCLC. A, Mutational landscape of EGFRm NSCLC in pCGP. Landscape figures represent the distribution of mutations among patients with EGFRm NSCLC, with findings clustered according to the number of previous lines of therapy. Each column represents an iteration of pCGP, and genes are clustered in rows according to the cellular pathway affected. Clinical metadata are represented in rows at the top of the diagram. The feature “EGFR activating” reflects EGFR mutations detected on pCGP assays. Several patients did not have EGFR mutations identified on pCGP but were included in this set as they were known to harbor EGFR activating mutations based on prior tissue NGS. We noted an early emergence of pathogenic alterations in genes in the PI3K pathway, late emergence of genomic alterations in the RAS pathway, and frequent cell-cycle gene alterations across settings. B–E, Key comutations in patients with EGFRm NSCLC by line of therapy. Pie–donut charts reflect the prevalence of EGFR comutations by the number of previous lines of TKI therapy. The inner circle in each chart reflects the cancer hallmark and gene families affected. The outer circle describes the individual genes altered. MET alterations are seen with increased frequency with later lines of therapy, whereas PI3K group alterations—predominantly PTEN mutations—become less frequent. DDR, DNA damage response.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Serial Plasma Comprehensive Genomic Profiling Captures Therapy Resistance and Guides Management of Non–Small Cell Lung Cancer
Comutations on pCGP in EGFRm NSCLC. A, Mutational landscape of EGFRm NSCLC in pCGP. Landscape figures represent the distribution of mutations among patients with EGFRm NSCLC, with findings clustered according to the number of previous lines of therapy. Each column represents an iteration of pCGP, and genes are clustered in rows according to the cellular pathway affected. Clinical metadata are represented in rows at the top of the diagram. The feature “EGFR activating” reflects EGFR mutations detected on pCGP assays. Several patients did not have EGFR mutations identified on pCGP but were included in this set as they were known to harbor EGFR activating mutations based on prior tissue NGS. We noted an early emergence of pathogenic alterations in genes in the PI3K pathway, late emergence of genomic alterations in the RAS pathway, and frequent cell-cycle gene alterations across settings. B–E, Key comutations in patients with EGFRm NSCLC by line of therapy. Pie–donut charts reflect the prevalence of EGFR comutations by the number of previous lines of TKI therapy. The inner circle in each chart reflects the cancer hallmark and gene families affected. The outer circle describes the individual genes altered. MET alterations are seen with increased frequency with later lines of therapy, whereas PI3K group alterations—predominantly PTEN mutations—become less frequent. DDR, DNA damage response.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 4 from Serial Plasma Comprehensive Genomic Profiling Captures Therapy Resistance and Guides Management of Non–Small Cell Lung Cancer
Association between pCGP parameters and OS. A, Kaplan–Meier survival curves for patients with no alterations identified on pCGP vs. any alteration identified on pCGP. B, Kaplan–Meier survival curves for patients with three or more mutations on pCGP or fewer than three mutations. C, Kaplan–Meier survival curves for patients who received targeted therapy matched to an alteration on pCGP and those who did not receive a matched therapy. D, Kaplan–Meier survival curves for patients who had alterations in the RAS pathway or those who had no RAS pathway alteration. P values are provided using the log-rank test; of note, comparisons in C and D did not include patients with zero alterations detected by pCGP.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Serial Plasma Comprehensive Genomic Profiling Captures Therapy Resistance and Guides Management of Non–Small Cell Lung Cancer
Association between pCGP parameters and OS. A, Kaplan–Meier survival curves for patients with no alterations identified on pCGP vs. any alteration identified on pCGP. B, Kaplan–Meier survival curves for patients with three or more mutations on pCGP or fewer than three mutations. C, Kaplan–Meier survival curves for patients who received targeted therapy matched to an alteration on pCGP and those who did not receive a matched therapy. D, Kaplan–Meier survival curves for patients who had alterations in the RAS pathway or those who had no RAS pathway alteration. P values are provided using the log-rank test; of note, comparisons in C and D did not include patients with zero alterations detected by pCGP.